Nippon Shinyaku Exercises Option for AB2 Bio's Tadekinig Alfa, Securing U.S. Commercialization Rights for Rare Autoinflammatory Diseases
核心洞察
Nippon Shinyaku has exercised its option rights to obtain exclusive U.S. commercialization rights for Tadekinig alfa from AB2 BIO (搜索) Ltd., building on a January 2025 option agreement.
Tadekinig alfa targets monogenic IL-18 driven Hyperinflammatory Syndrome (搜索) in patients with NLRC4 and XIAP mutations, two rare hereditary autoinflammatory diseases with no currently approved therapies.
The recombinant human IL-18 (搜索) binding protein has received Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease designations in the United States.
Nippon Shinyaku Co., Ltd., the parent company of NS Pharma (搜索), Inc., has exercised its option rights under an agreement with Switzerland-based AB2 BIO (搜索) Ltd., securing exclusive commercialization rights for Tadekinig alfa in the United States. The announcement, made on July 30, 2026, marks a significant step toward delivering a targeted therapy for patients suffering from monogenic IL-18 driven Hyperinflammatory Syndrome (搜索) associated with NLRC4 and XIAP mutations.
The option agreement was originally entered into in January 2025. With the exercise of these rights, Nippon Shinyaku positions itself to bring a first-in-class therapy to an underserved rare disease population that currently lacks any approved pharmacological intervention.
A Novel Mechanism Targeting IL-18 (搜索)-Driven Inflammation
Tadekinig alfa is a recombinant human IL-18 (搜索) binding protein designed to suppress pathological immune and inflammatory responses by specifically binding to excessively produced interleukin-18 (IL-18). In patients with NLRC4 mutations and XIAP deficiency (搜索), elevated IL-18 levels drive a cascade of inflammatory symptoms that typically manifest in infancy and persist throughout life.
NLRC4 mutation (搜索) and XIAP deficiency (搜索) are rare, serious hereditary autoinflammatory diseases. According to the companies, there are currently no approved therapies specifically indicated for either condition, underscoring the high unmet medical need.
Regulatory Designations and Path Forward
Tadekinig alfa has already secured multiple regulatory designations from the U.S. Food and Drug Administration, including Orphan Drug Designation, Breakthrough Therapy Designation, and Rare Pediatric Disease Designation. The therapy has also received Orphan Drug Designation in Europe. These designations reflect both the severity of the target conditions and the promising evidence supporting the drug's therapeutic potential.
Following regulatory approval in the United States, Tadekinig alfa is expected to be commercialized by NS Pharma (搜索), Inc., a wholly owned subsidiary of Nippon Shinyaku based in Paramus, New Jersey.
Leadership Perspectives
"The exercise of this option agreement further exemplifies our long-term commitment to shepherding therapeutic advances into novel treatments that profoundly improve the lives of rare disease patients and address unmet needs," said Dr. Yukiteru Sugiyama, President of NS Pharma (搜索). "We are proud to partner with AB2 BIO (搜索) to bring this much needed treatment to an underserved patient population."
AB2 BIO (搜索), founded in 2010 and headquartered at the Innovation Park at the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, is advancing Tadekinig alfa across a wide range of IL-18 (搜索) mediated hyperinflammatory diseases and conditions, including rare orphan diseases at both clinical and preclinical stages.
Nippon Shinyaku, guided by its business philosophy of "Helping people lead healthier, happier lives," continues to focus on creating unique medicines for patients and families affected by serious illness. NS Pharma (搜索), backed by over one hundred years of development expertise, is dedicated to delivering life-changing care to people living with complex, rare diseases.